This is a demo store. No orders will be fulfilled.

Vactosertib Hydrochloride - 99%, high purity , CAS No.1352610-25-3

    Grade & Purity:
  • ≥99%
In stock
Item Number
V648276
Grouped product items
SKU Size
Availability
Price Qty
V648276-2mg
2mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$90.90
V648276-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$130.90
V648276-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$220.90
V648276-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$490.90
V648276-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$816.90
V648276-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,140.90

Basic Description

Specifications & Purity ≥99%
Biochemical and Physiological Mechanisms Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC 50 of 12.9 nM. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 ( IC 50 of 17.3 nM) at nanomol
Storage Temp Store at -20°C,Argon charged
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Product Description

Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC 50 of 12.9 nM. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 ( IC 50 of 17.3 nM) at nanomolar concentrations. Vactosertib Hydrochloride has potently antimetastatic activity and anticancer effect

In Vitro

Vactosertib (10-1000 nM; 30 minutes; 4T1 cells) treatment blocks the TGFβ-induced phosphorylation of Smad2 or Smad3 in a dose-dependent manner in 4T1 cells. Vactosertib suppresses the TGFβ-induced nuclear translocation of Smad2/3 in 4T1 cells and MCF10A cells. The IC 50 value of Vactosertib on pSmad3 in 4T1 cells is 10-30 nM. Vactosertib abrogates TGFb1-induced tumor cell migration and invasion. TGFβ1 downregulated the mRNA level of CDH1 and upregulated the mRNA levels of FN1, HMGA2 (high-mobility group AT-hook 2), SNAI1, and SNAI2 (Snail family zinc finger 1 and 2, respectively). Moreover, Vactosertib abolishes the TGFβ1-induced effects on genes related to epithelial-to-mesenchymal transition (EMT). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: 4T1 cells Concentration: 10 nM, 30 µM, 50 nM, 100 µM, 300 nM, 500 nM, 1000 nM Incubation Time: 30 minutes Result: Blocked the TGFb-induced phosphorylation of Smad2 or Smad3 in a dose-dependent manner.

In Vivo

Vactosertib (40 mg/kg; intraperitoneal injection; every other day; for 10 weeks; MMTV/c-Neu female mice) treatment inhibits Smad/TGFβ signaling, cell migration, invasion, and lung metastasis in MMTV/c-Neu mice . Vactosertib also inhibits the epithelial-to-mesenchymal transition (EMT) in both TGFβ-treated breast cancer cells and 4T1 orthotopic-grafted mice. Furthermore, Vactosertib enhances cytotoxic T lymphocyte activity in 4T1 orthotopic-grafted mice and increased the survival time of 4T1-Luc and 4T1 breast tumor-bearing mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mammary tumor virus (MMTV)/c-Neu female mice (32-week-old) Dosage: 40 mg/kg Administration: Intraperitoneal injection; every other day; for 10 weeks Result: Inhibited Smad/TGFβ signaling, cell migration, invasion, and lung metastasis in MMTV/c-Neu mice.

Form:Solid

IC50& Target:ALK5 12.9 nM (IC 50 )

Taxonomic Classification

Taxonomy Tree

Kingdom Organic compounds
Superclass Organoheterocyclic compounds
Class Triazolopyridines
Subclass Not available
Intermediate Tree Nodes Not available
Direct Parent Triazolopyridines
Alternative Parents Phenylalkylamines  Aniline and substituted anilines  2,4,5-trisubstituted imidazoles  Secondary alkylarylamines  Methylpyridines  Fluorobenzenes  Aryl fluorides  Triazoles  Heteroaromatic compounds  Azacyclic compounds  Organofluorides  Hydrochlorides  Hydrocarbon derivatives  Organic anions  
Molecular Framework Aromatic heteropolycyclic compounds
Substituents Triazolopyridine - 2,4,5-trisubstituted-imidazole - Trisubstituted imidazole - Aniline or substituted anilines - Phenylalkylamine - Halobenzene - Secondary aliphatic/aromatic amine - Fluorobenzene - Methylpyridine - Aralkylamine - Monocyclic benzene moiety - Aryl fluoride - Benzenoid - Pyridine - Aryl halide - Imidazole - 1,2,4-triazole - Azole - Heteroaromatic compound - Azacycle - Secondary amine - Organonitrogen compound - Amine - Hydrochloride - Organic nitrogen compound - Hydrocarbon derivative - Organofluoride - Organohalogen compound - Organic anion - Aromatic heteropolycyclic compound
Description This compound belongs to the class of organic compounds known as triazolopyridines. These are compounds containing a triazole ring fused to a pyridine ring. Triazole is a five-membered ring consisting of two carbon atoms and three nitrogen atoms. Pyridine is a 6-membered ring consisting of five carbon atoms and one nitrogen center.
External Descriptors Not available

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Names and Identifiers

IUPAC Name 2-fluoro-N-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methyl]aniline;hydrochloride
INCHI InChI=1S/C22H18FN7.ClH/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23;/h2-10,12-13,24H,11H2,1H3,(H,28,29);1H
InChIKey UDRJLVATGDHMJM-UHFFFAOYSA-N
Smiles CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4.Cl
Isomeric SMILES CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4.Cl
PubChem CID 54766014
Molecular Weight 435.88

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Chemical and Physical Properties

Solubility H2O : 50 mg/mL (114.71 mM; Need ultrasonic) DMSO : 50 mg/mL (114.71 mM; Need ultrasonic)
Molecular Weight 435.900 g/mol
XLogP3
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 6
Rotatable Bond Count 5
Exact Mass 435.137 Da
Monoisotopic Mass 435.137 Da
Topological Polar Surface Area 83.800 Ų
Heavy Atom Count 31
Formal Charge 0
Complexity 566.000
Isotope Atom Count 0
Defined Atom Stereocenter Count 0
Undefined Atom Stereocenter Count 0
Defined Bond Stereocenter Count 0
Undefined Bond Stereocenter Count 0
The total count of all stereochemical bonds 0
Covalently-Bonded Unit Count 2

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.